Navigation Links
Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
Date:4/15/2011

INDIANAPOLIS, April 15, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), under investigation for the treatment of exocrine pancreatic insufficiency (EPI).

The complete response letter communicated the need for Lilly to conduct an additional clinical trial prior to a re-submission.

"Lilly is looking forward to further discussion with the FDA to address the items outlined in the letter and provide the requested information as quickly as possible," said Eiry Roberts, M.D., Vice President, Autoimmune, Bone-Muscle-Joint, Liprotamase Product Development at Lilly.  "We are committed to working with the Agency and the cystic fibrosis community to make this important treatment option available to patients."

People with EPI have very low levels or none of the key digestive enzymes made by the pancreas - lipase, amylase and protease - in their small intestine, resulting in improper digestion and absorption of fat, carbohydrates and proteins, often requiring treatment with PERTs. EPI occurs very frequently in patients with cystic fibrosis (a life-threatening genetic disorder) and in other diseases including chronic pancreatitis and pancreatectomy.

About Liprotamase

Liprotamase is an oral, non-porcine (not made from harvesting the pancreas of pigs), biotechnology-derived, pancreatic enzyme replacement therapy (PERT) developed to treat patients with EPI associated with cystic fibrosis, chronic pancreatitis and pancreatectomy.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about liprotamase for the treatment of exocrine pancreatic insufficiency (EPI). It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that liprotamase will be approved by the FDA on the anticipated timeline or at all, or that it will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. The companies undertake no duty to update forward-looking statements.

P-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avant Healthcare Marketing Receives 2010 Lilly Global Sustained Supplier Award
2. Lilly Confirms Date and Conference Call for First-Quarter 2011 Financial Results Announcement
3. Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
4. Lillys Connecting Hearts Abroad Program Sends Employees on Global Service Assignments
5. Lilly and Avid Receive Complete Response Letter from FDA for Amyvid™ (florbetapir F 18 injection)
6. NAFE Names Lilly to Top 50 Companies for Executive Women
7. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
8. Lilly Announces New Vice President of Oncology Research
9. Lilly CEO Calls for Biopharmaceutical Industry Changes and Policies That Encourage Medical Innovation
10. Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines
11. Lilly Announces Senior Leadership Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... it will release fourth quarter and yearly financial ... 2017. AcelRx management will host an investment-community conference ... Pacific Time) on March 2 nd 2017 ...
(Date:2/23/2017)... -- ... Research and Markets has announced the addition of the "Global Antifungal ... to their offering. The Global Antifungal Drugs Market is ... decade to reach approximately $12.8 billion by 2025. ... given segments on global as well as regional levels presented in the ...
(Date:2/23/2017)... New York , February 23, 2017 ... Cardiac Holter Monitor Market are GE Healthcare, Koninklijke Philips ... of about 48% in the global market in 2015. ... the two key factors assessed to be aiding these ... Market Research states that the players in the global ...
Breaking Medicine Technology:
(Date:2/22/2017)... New York, NY (PRWEB) , ... February 22, ... ... academics, professional life and athletics. It’s enough to overwork even the sharpest brain. ... ingredients that offer peak healthy activity without over clocking the brain. Each capsule ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the award-winning TV ... feature Heroes On The Water (HOW), a non-profit organization dedicated to helping military veterans ... series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish with war ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... chronic conditions reported skipping doses or not filling a prescription because they could ... rates of cost-related problems getting medications were 30-60%*. At the same ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Sideline Products ... the company met national TV host Tom Seay and his production crew. Tom ... favorite among equestrians around the world. Saddle Sidekicks will be featured on April ...
Breaking Medicine News(10 mins):